Collaborations

Partnering to accelerate the development of groundbreaking treatments

Chimerix is actively seeking opportunities to collaborate in order to increase innovation and efficiencies to help speed the development of potential life-saving medicines to patients while creating long-term value. With a focus on extending patients’ lives who are suffering from life-threatening diseases, we have specific interest in partnering for clinical-stage assets in oncology and biodefense where we can leverage our substantial expertise. For more information about our interests and how we might work together to advance innovation, please contact Mike Andriole, Chief Business Officer, at mandriole@chimerix.com.

Key benefits of collaborating with Chimerix include:

  • Strong culture of execution
  • Extensive clinical development and regulatory experience
  • Creativity in constructing partnerships
  • Commitment to professional alliance management
  • Public company infrastructure

Oncology Collaborations

Oncoceutics, Inc.

In January 2021, Chimerix announced that the Company has entered into a definitive agreement to acquire Oncoceutics, Inc., a privately-held, clinical-stage biotechnology company developing imipridones, a novel class of compounds that selectively induce cell death of several cancers. Read the announcement.

Cantex Pharmaceuticals

In July 2019, Chimerix announced exclusive worldwide rights to develop and commercialize CX-01 (also known as dociparstat, or DSTAT) in acute myeloid leukemia (AML). Read the announcement.

Biodefense Collaborations

BARDA

In 2011, Chimerix initiated a partnership with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop TEMBEXA as a medical countermeasure to treat smallpox outbreaks due to a bioterror event or accidental release. In June 2021, TEMBEXA was approved by the U.S. FDA. Read the announcement

Other Collaborations

SymBio Pharmaceuticals

In Sept. 2019, Chimerix announced a global license agreement with SymBio Pharmaceuticals, Ltd. (SymBio), under which SymBio has exclusively licensed the worldwide rights to develop, manufacture, and commercialize BCV in all human indications, excluding the prevention and treatment of smallpox. Moving forward, SymBio will be responsible for all future development and commercialization as well as manufacturing associated with BCV in its licensed indications. Read the announcement.